Key facts
- This page summarizes Ehong Gu's Form 4 filing for LianBio (LIANY).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 11 Apr 2024, 16:10.
Ehong Gu - 02 Jan 2024 Form 4 Insider Report for LianBio (LIANY)
- Reporting relationship
- Interim CFO
- Issuer ticker
- LIANY
- Reported as of
- 02 Jan 2024
- Net transaction value
- -$13,237
- SEC form
- 4
- Accepted by SEC
- 11 Apr 2024, 16:10:11 UTC
- Prior SEC filing
- 26 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brianne Jahn, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ehong Gu filed Form 4 for LianBio (LIANY) on 11 Apr 2024.
Change
- Previous filing in this sequence was filed on 26 Dec 2023.
- Current net transaction value: -$13,237.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LIAN
transaction
Ordinary Shares
Sale
- Transaction value
- $7,513
- Shares
- -1,731
- Change %
- -2.2%
- Price
- $4.34
- Shares after
- 76,762
- Date
- 02 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
LIAN
transaction
Ordinary Shares
Disposed to Issuer
- Transaction value
- $5,724
- Shares
- -17,889
- Change %
- -100%
- Price
- $0.3200*
- Shares after
- 0
- Date
- 09 Apr 2024
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents the sale of shares to cover personal income tax obligations upon vesting of restricted share units ('RSUs') as required pursuant to the terms of Ms. Gu's RSU award agreement. 41,078 RSUs were granted to Ms. Gu under the LianBio 2021 Equity Incentive Plan (the 'Plan') on December 31, 2021, 25% of which vested on each of December 31, 2022 and 2023 with the remainder to vest in 25% annual installments and to be fully vested on December 31, 2025, subject to Ms. Gu's providing continuous service to the Issuer on each such date. On March 22, 2024, the board of directors of the Issuer resolved to terminate the Plan and any unvested RSUs granted thereunder in accordance with the terms of the Plan, effective as of March 24, 2024. In accordance with this determination, 58,873 unvested RSUs previously reported as beneficially owned by Ms. Gu were cancelled. Ms. Gu received no value in exchange for the cancellation of the unvested RSUs.